Skip to main content
SpringerLink
Log in

Olanzapine long-acting injection stands out

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ascher-Svanum H, Furiak NM, Klein RW, Montgomery W, Smolen LJ, Lawson AH, Conley RR.Cost-effectiveness of olanzapine long-acting injection in the treatment of non-adherence patients with schizophrenia in the United States. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 176 abstr. PMH21, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olanzapine long-acting injection stands out. Pharmacoecon. Outcomes News 579, 6 (2009). https://doi.org/10.2165/00151234-200905790-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905790-00009

Keywords

Search

Navigation